Newsfeeds - Spark Newswire

1 minute read

Forge Global Holdings Q4 EPS $(0.15), Inline, Sales $16.70M Miss $17.88M Estimate

Today, 4:31 AM

Forge Global Holdings (NYSE:FRGE) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. The company reported quarterly sales of $16.70 million which missed the analyst consensus

FRGE

2 minute read

Forge Announces Strategic Evolution To Deliver Customer-Centric Solutions, Drive Efficiencies Across The Business

By Benzinga Newsdesk

Today, 4:31 AM

Forge Global Holdings, Inc., ("Forge" or the "Company") (NYSE:FRGE), a global private securities marketplace, today announced its customer-centric strategic evolution ("The Strategic

FRGE

7 minute read

Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 4:31 AM

During Wednesday's session, 107 stocks hit new 52-week lows.

AAP

1 minute read

UBS Initiates Coverage On Forge Global Holdings with Neutral Rating, Announces Price Target of $1.75

By Benzinga Newsdesk

Today, 4:31 AM

UBS analyst Alex Kramm initiates coverage on Forge Global Holdings (NYSE:FRGE) with a Neutral rating and announces Price Target of $1.75.

FRGE

1 minute read

Piper Sandler Initiates Coverage On Forge Global Holdings with Neutral Rating, Announces Price Target of $1.75

By Benzinga Newsdesk

Today, 4:31 AM

Piper Sandler analyst Richard Repetto initiates coverage on Forge Global Holdings (NYSE:FRGE) with a Neutral rating and announces Price Target of $1.75.

FRGE

1 minute read

Forge Global Holdings Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $15.80M Miss $16.60M Estimate

By Benzinga Newsdesk

Today, 4:31 AM

Forge Global Holdings (NYSE:FRGE) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 20 percent decrease over losses of $(0.10) per share from

FRGE

6 minute read

Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:31 AM

Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case.

ACOR